

**Clinical trial results:
Prospective Randomized Phase-III-Trial of Paclitaxel plus Topotecan
versus Topotecan plus Cisplatin in Recurrent or Persistent Cervical
Carcinoma****Summary**

EudraCT number	2006-000349-20
Trial protocol	DE AT BE
Global end of trial date	02 April 2014

Results information

Result version number	v1 (current)
This version publication date	29 March 2022
First version publication date	29 March 2022

Trial information**Trial identification**

Sponsor protocol code	IFG-01-0106
-----------------------	-------------

Additional study identifiers

ISRCTN number	ISRCTN77165120
ClinicalTrials.gov id (NCT number)	NCT01405235
WHO universal trial number (UTN)	-

Notes:

Sponsors

Sponsor organisation name	Institut für Frauengesundheit GmbH
Sponsor organisation address	Universitätsstraße 21-23, Erlangen, Germany, 91054
Public contact	Clinical Trial Information, Institut für Frauengesundheit GmbH, studien@ifg-erlangen.de
Scientific contact	Clinical Trial Information, Institut für Frauengesundheit GmbH, studien@ifg-erlangen.de

Notes:

Paediatric regulatory details

Is trial part of an agreed paediatric investigation plan (PIP)	No
Does article 45 of REGULATION (EC) No 1901/2006 apply to this trial?	No
Does article 46 of REGULATION (EC) No 1901/2006 apply to this trial?	No

Notes:

Results analysis stage

Analysis stage	Final
Date of interim/final analysis	23 February 2022
Is this the analysis of the primary completion data?	No
Global end of trial reached?	Yes
Global end of trial date	02 April 2014
Was the trial ended prematurely?	Yes

Notes:

General information about the trial

Main objective of the trial:

Comparison of overall survival

Protection of trial subjects:

The study was conducted in accordance with the ethical principles that have their origin in the Declaration of Helsinki and the applicable guidelines of the International Conference on Harmonization Good Clinical Practice (GCP) concerning informed consent and the protection of rights of human patients and other relevant international guidelines.

Background therapy: -

Evidence for comparator:

The studies GOG 169 and 179 demonstrated that a combination of paclitaxel and cisplatin was superior to a cisplatin monotherapy with respect to therapeutic response and progression-free survival, as was a combination of topotecan and cisplatin with respect to therapeutic response, progression-free survival, and total survival. To achieve further improvement in total survival and to answer questions regarding the value of using a platinum-free combination, we conducted this trial to compare the efficacy of a platinum-free combination of paclitaxel and topotecan to a combination of cisplatin and topotecan.

Actual start date of recruitment	22 January 2007
Long term follow-up planned	Yes
Long term follow-up rationale	Safety, Efficacy
Long term follow-up duration	15 Months
Independent data monitoring committee (IDMC) involvement?	Yes

Notes:

Population of trial subjects

Subjects enrolled per country

Country: Number of subjects enrolled	Austria: 34
Country: Number of subjects enrolled	Belgium: 12
Country: Number of subjects enrolled	Germany: 127
Worldwide total number of subjects	173
EEA total number of subjects	173

Notes:

Subjects enrolled per age group

In utero	0
Preterm newborn - gestational age < 37 wk	0

Newborns (0-27 days)	0
Infants and toddlers (28 days-23 months)	0
Children (2-11 years)	0
Adolescents (12-17 years)	0
Adults (18-64 years)	155
From 65 to 84 years	18
85 years and over	0

Subject disposition

Recruitment

Recruitment details:

The clinical trial was conducted in 52 trials sites of the organ-specific uterine malignoma group and the organ-specific ovarian group of the AGO and other clinics with sufficient experience in conducting clinical studies. Recruitment started from January 2007 and was suspended on 31.12.2012.

Pre-assignment

Screening details:

A total of 189 patients were assessed for eligibility. 11 Patients declined study participation and 5 subjects were identified as screening failures. Therefore, 173 patients were assessed.

Period 1

Period 1 title	Overall trial (overall period)
Is this the baseline period?	Yes
Allocation method	Randomised - controlled
Blinding used	Not blinded

Arms

Are arms mutually exclusive?	Yes
Arm title	Paclitaxel/Topotecan

Arm description:

Paclitaxel 70 mg/m²/d i.v. was administered over one hour and topotecan 1.75 mg/m²/d i.v. over 30 min. on days 1, 8, and 15; this cycle was repeated every four weeks for six cycles or until there was evidence of disease progression, or until unacceptable adverse effects prohibited further therapy. Maximum body surface area used for dose calculations was 2.0 m².

Treatment continued until completion of a maximum of six cycles. The therapy discontinued prior to the completion of six cycles if there was evidence of disease progression, or if unacceptable adverse effects prohibited further therapy. Patients with continued response or stable disease could continue to participate in the study for an additional three cycles beyond the original six cycles with consent of the Study Director.

Arm type	Experimental
Investigational medicinal product name	Paclitaxel
Investigational medicinal product code	
Other name	
Pharmaceutical forms	Solution for solution for infusion
Routes of administration	Solution for infusion , Intravenous use

Dosage and administration details:

Paclitaxel 70 mg/m²/d i.v. was administered over one hour on days 1, 8, and 15; this cycle was repeated every four weeks for six cycles or until there was evidence of disease progression, or until unacceptable adverse effects prohibited further therapy. Maximum body surface area used for dose calculations was 2.0 m².

Investigational medicinal product name	Topotecan
Investigational medicinal product code	
Other name	Hycamtin
Pharmaceutical forms	Solvent for solution for infusion
Routes of administration	Intravenous use, Solution for infusion

Dosage and administration details:

Topotecan administered 1.75 mg/m²/d i.v. over 30 min. on Days 1, 8, and 15; this cycle will be repeated every 4 weeks for 6 cycles or until there is evidence of disease progression, or until unacceptable adverse effects prohibit further therapy. Maximum body surface area used for dose calculations will be 2.0 m².

Arm title	Cisplatin/Topotecan
------------------	---------------------

Arm description:

Topotecan 0.75 mg/m²/d was administered over 30 min. on days 1, 2, and 3 and cisplatin 50 mg/m² i.v. on day 1; this cycle repeated every three weeks for a maximum of six cycles or until there was evidence of disease progression, or until unacceptable adverse effects prohibited further therapy. Maximum body surface area used for dose calculations was 2.0 m².

Treatment continued until completion of a maximum of six cycles. The therapy discontinued prior to the completion of six cycles if there was evidence of disease progression, or if unacceptable adverse effects prohibited further therapy. Patients with continued response or stable disease could continue to participate in the study for an additional three cycles beyond the original six cycles with consent of the Study Director.

Arm type	Active comparator
Investigational medicinal product name	Topotecan
Investigational medicinal product code	
Other name	Hycamtin
Pharmaceutical forms	Solvent for solution for infusion
Routes of administration	Intravenous use, Solution for infusion

Dosage and administration details:

Topotecan administered 1.75 mg/m²/d i.v. over 30 min. on Days 1, 8, and 15; this cycle will be repeated every 4 weeks for 6 cycles or until there is evidence of disease progression, or until unacceptable adverse effects prohibit further therapy. Maximum body surface area used for dose calculations will be 2.0 m².

Investigational medicinal product name	Cisplatin
Investigational medicinal product code	
Other name	
Pharmaceutical forms	Solution for solution for infusion
Routes of administration	Intravenous use, Solution for infusion

Dosage and administration details:

Cisplatin 50 mg/m² i.v. was administered on day 1; this cycle repeated every three weeks for a maximum of six cycles or until there was evidence of disease progression, or until unacceptable adverse effects prohibited further therapy. Maximum body surface area used for dose calculations was 2.0 m².

Number of subjects in period 1	Paclitaxel/Topotecan	Cisplatin/Topotecan
Started	88	85
Completed	83	78
Not completed	5	7
Did not receive assigned treatment	5	7

Baseline characteristics

Reporting groups

Reporting group title	Paclitaxel/Topotecan
-----------------------	----------------------

Reporting group description:

Paclitaxel 70 mg/m²/d i.v. was administered over one hour and topotecan 1.75 mg/m²/d i.v. over 30 min. on days 1, 8, and 15; this cycle was repeated every four weeks for six cycles or until there was evidence of disease progression, or until unacceptable adverse effects prohibited further therapy. Maximum body surface area used for dose calculations was 2.0 m².

Treatment continued until completion of a maximum of six cycles. The therapy discontinued prior to the completion of six cycles if there was evidence of disease progression, or if unacceptable adverse effects prohibited further therapy. Patients with continued response or stable disease could continue to participate in the study for an additional three cycles beyond the original six cycles with consent of the Study Director.

Reporting group title	Cisplatin/Topotecan
-----------------------	---------------------

Reporting group description:

Topotecan 0.75 mg/m²/d was administered over 30 min. on days 1, 2, and 3 and cisplatin 50 mg/m² i.v. on day 1; this cycle repeated every three weeks for a maximum of six cycles or until there was evidence of disease progression, or until unacceptable adverse effects prohibited further therapy. Maximum body surface area used for dose calculations was 2.0 m².

Treatment continued until completion of a maximum of six cycles. The therapy discontinued prior to the completion of six cycles if there was evidence of disease progression, or if unacceptable adverse effects prohibited further therapy. Patients with continued response or stable disease could continue to participate in the study for an additional three cycles beyond the original six cycles with consent of the Study Director.

Reporting group values	Paclitaxel/Topotecan	Cisplatin/Topotecan	Total
Number of subjects	88	85	173
Age categorical			
Units: Subjects			
Adults (18-64 years)			0
From 65-84 years			0
Age continuous			
Units: years			
arithmetic mean	50.4	49.0	-
standard deviation	± 11.1	± 11.0	-
Gender categorical			
Units: Subjects			
Female	88	85	173
Male	0	0	0
ECOG			
Units: Subjects			
ECOG 0	44	38	82
ECOG 1	37	39	76
ECOG 2	7	8	15
concomitant diseases			
Number of concomitant diseases			
Units: Subjects			
N=0	32	33	65
N=1	25	24	49
N=2+	31	28	59
Disease status			

Units: Subjects			
Disatant metastasis	66	62	128
Local recurrence	22	23	45
BMI			
Units: kg/m2			
arithmetic mean	26.2	25.6	
standard deviation	± 6.5	± 6.6	-

End points

End points reporting groups

Reporting group title	Paclitaxel/Topotecan
-----------------------	----------------------

Reporting group description:

Paclitaxel 70 mg/m²/d i.v. was administered over one hour and topotecan 1.75 mg/m²/d i.v. over 30 min. on days 1, 8, and 15; this cycle was repeated every four weeks for six cycles or until there was evidence of disease progression, or until unacceptable adverse effects prohibited further therapy. Maximum body surface area used for dose calculations was 2.0 m².

Treatment continued until completion of a maximum of six cycles. The therapy discontinued prior to the completion of six cycles if there was evidence of disease progression, or if unacceptable adverse effects prohibited further therapy. Patients with continued response or stable disease could continue to participate in the study for an additional three cycles beyond the original six cycles with consent of the Study Director.

Reporting group title	Cisplatin/Topotecan
-----------------------	---------------------

Reporting group description:

Topotecan 0.75 mg/m²/d was administered over 30 min. on days 1, 2, and 3 and cisplatin 50 mg/m² i.v. on day 1; this cycle repeated every three weeks for a maximum of six cycles or until there was evidence of disease progression, or until unacceptable adverse effects prohibited further therapy. Maximum body surface area used for dose calculations was 2.0 m².

Treatment continued until completion of a maximum of six cycles. The therapy discontinued prior to the completion of six cycles if there was evidence of disease progression, or if unacceptable adverse effects prohibited further therapy. Patients with continued response or stable disease could continue to participate in the study for an additional three cycles beyond the original six cycles with consent of the Study Director.

Subject analysis set title	ITT Set
----------------------------	---------

Subject analysis set type	Intention-to-treat
---------------------------	--------------------

Subject analysis set description:

ITT population 1 are all patients included in the interim analysis (n=172) and ITT population 2 (ITT2; n=173) is the total study population

Subject analysis set title	Safety analysis set
----------------------------	---------------------

Subject analysis set type	Safety analysis
---------------------------	-----------------

Subject analysis set description:

The safety evaluation was performed in all randomized patients who were treated with at least one cycle of chemotherapy (n=161 (Safety Population); Arm A (Paclitaxel and Topotecan) 83 patients and Arm B (control group; Topotecan and Cisplatin) 78 patients).

Primary: Overall Survival

End point title	Overall Survival
-----------------	------------------

End point description:

Overall survival is the observed length of life from randomization to death or the date of last contact. In the planned interim analysis, the primary efficacy analysis (primary study aim) was performed with all 172 patients (Intention to treat population, ITT population 1), Arm A including 87 patients, Arm B including 85 patients. The ITT population 1 includes all patients (172) who gave informed consent and who were randomized into one of the treatment arms at the time of the interim analysis.

End point type	Primary
----------------	---------

End point timeframe:

Duration of trial

End point values	Paclitaxel/Topotecan	Cisplatin/Topotecan		
Subject group type	Reporting group	Reporting group		
Number of subjects analysed	87 ^[1]	85 ^[2]		
Units: month				
median (confidence interval 95%)	9.6 (7.2 to 12.4)	12.0 (9.1 to 16.3)		

Notes:

[1] - Patients included in Arm A

[2] - Patients included in Arm B

Statistical analyses

Statistical analysis title	Overall Survival
Comparison groups	Paclitaxel/Topotecan v Cisplatin/Topotecan
Number of subjects included in analysis	172
Analysis specification	Pre-specified
Analysis type	other
P-value	= 0.33
Method	Logrank

Secondary: 6 month PFS rate

End point title	6 month PFS rate
End point description:	
Progression-free survival is the period from study entry until disease progression, death, or date of last contact.	
In the final analysis at the end of the study, the secondary study aims were analyzed with all 173 patients (ITT population 2), Arm A including 88 patients, Arm B including 85 patients. The ITT population 2 includes all patients (173) who gave informed consent and who were randomized into one of the treatment arms during the whole study.	
End point type	Secondary
End point timeframe:	
Duration of trial	

End point values	Paclitaxel/Topotecan	Cisplatin/Topotecan		
Subject group type	Reporting group	Reporting group		
Number of subjects analysed	88	85		
Units: percent				
number (confidence interval 95%)	75.66 (71.73 to 79.59)	75.86 (72.20 to 79.53)		

Statistical analyses

No statistical analyses for this end point

Secondary: 12 month PFS rate

End point title	12 month PFS rate
End point description:	
In the final analysis at the end of the study, the secondary study aims were analyzed with all 173 patients (ITT population 2), Arm A including 88 patients, Arm B including 85 patients. The ITT population 2 includes all patients (173) who gave informed consent and who were randomized into one of the treatment arms during the whole study.	
End point type	Secondary
End point timeframe:	
Duration of trial	

End point values	Paclitaxel/Topotecan	Cisplatin/Topotecan		
Subject group type	Reporting group	Reporting group		
Number of subjects analysed	88	85		
Units: percent				
number (confidence interval 95%)	14 (8 to 24)	10 (5 to 19)		

Statistical analyses

No statistical analyses for this end point

Secondary: 24 month PFS rate

End point title	24 month PFS rate
End point description:	
In the final analysis at the end of the study, the secondary study aims were analyzed with all 173 patients (ITT population 2), Arm A including 88 patients, Arm B including 85 patients. The ITT population 2 includes all patients (173) who gave informed consent and who were randomized into one of the treatment arms during the whole study.	
End point type	Secondary
End point timeframe:	
Duration of Trial	

End point values	Paclitaxel/Topotecan	Cisplatin/Topotecan		
Subject group type	Reporting group	Reporting group		
Number of subjects analysed	88	85		
Units: percent				
number (confidence interval 95%)	6 (3 to 15)	6 (2 to 15)		

Statistical analyses

No statistical analyses for this end point

Secondary: Best overall response

End point title	Best overall response
-----------------	-----------------------

End point description:

In the final analysis at the end of the study, the secondary study aims were analyzed with all 173 patients (ITT population 2), Arm A including 88 patients, Arm B including 85 patients. The ITT population 2 includes all patients (173) who gave informed consent and who were randomized into one of the treatment arms during the whole study.

Measurement of the longest dimension of each lesion size was required for follow-up. Change in the sum of these dimensions afforded some estimate of change in tumor size and, hence, of therapeutic efficacy. All assessments were made using the same techniques as were used for the baseline. These changes in an individual case had to be reported in terms of the best response achieved by that case since entering the study.

End point type	Secondary
----------------	-----------

End point timeframe:

Duration of trial

End point values	Paclitaxel/Topotecan	Cisplatin/Topotecan		
Subject group type	Reporting group	Reporting group		
Number of subjects analysed	66 ^[3]	67 ^[4]		
Units: number of patients				
complete response	1	2		
partial remission	11	13		
stable disease	21	20		
progression	29	26		
symptomatic deterioration	3	6		
not evaluable	1	0		

Notes:

[3] - Only patients with at least one further tumor assessment since baseline were included.

[4] - Only patients with at least one further tumor assessment since baseline were included.

Statistical analyses

No statistical analyses for this end point

Secondary: Quality of Life

End point title	Quality of Life
-----------------	-----------------

End point description:

Association between treatment arm and cQOL was analyzed using linear mixed models with TOI as target variable. First, a linear mixed model was fitted with patient as random effect and treatment arm (categorical, Arm A vs Arm B), TOI before treatment (continuous), time (categorical; before chemotherapy cycle 2, before chemotherapy cycle 5, 9 months after randomization) and the interaction between treatment arm and time as fixed effect. Next, a linear mixed model with the same fixed effects but without the interaction term was fitted. Both models were compared using the likelihood ratio test. If the p value was significant, adjusted mean TOI in both treatment arms and the mean difference between treatment arms with corresponding 95% CI were estimated for each time point using the interaction model. Otherwise, respective overall mean TOI values were estimated using the reduced regression model. The models were fitted by maximum likelihood instead of of restricted maximum likelihood.

End point type	Secondary
----------------	-----------

End point timeframe:

before chemotherapy cycle 2, before chemotherapy cycle 5, 9 months after randomization

End point values	Paclitaxel/Topotecan	Cisplatin/Topotecan		
Subject group type	Reporting group	Reporting group		
Number of subjects analysed	34 ^[5]	38 ^[6]		
Units: trial outcome index				
arithmetic mean (confidence interval 95%)	75.66 (71.73 to 79.59)	75.86 (72.20 to 79.53)		

Notes:

[5] - Patients with TOI information before chemotherapy and at least one followup TOI assessment.

[6] - Patients with TOI information before chemotherapy and at least one followup TOI assessment.

Statistical analyses

Statistical analysis title	Quality of life
Comparison groups	Paclitaxel/Topotecan v Cisplatin/Topotecan
Number of subjects included in analysis	72
Analysis specification	Post-hoc
Analysis type	superiority
P-value	= 0.9
Method	Likelihood ratio test
Parameter estimate	Mean difference (final values)
Point estimate	0.21
Confidence interval	
level	95 %
sides	2-sided
lower limit	-4.67
upper limit	5.09

Adverse events

Adverse events information

Timeframe for reporting adverse events:

The investigator must report all AEs occurring during the clinical study or within 30 days after administration of the last dose of the study drug, regardless of causality.

Adverse event reporting additional description:

The safety evaluation was performed in all randomized patients who were treated with at least one cycle of chemotherapy (n=161 (Safety Population); Arm A (Paclitaxel and Topotecan) 83 patients and Arm B (control group; Topotecan and Cisplatin) 78 patients).

Assessment type	Systematic
-----------------	------------

Dictionary used

Dictionary name	MedDRA
Dictionary version	19.1

Reporting groups

Reporting group title	Arm A (Paclitaxel and Topotecan)
-----------------------	----------------------------------

Reporting group description: -

Reporting group title	Arm B (Topotecan and Cisplatin)
-----------------------	---------------------------------

Reporting group description: -

Serious adverse events	Arm A (Paclitaxel and Topotecan)	Arm B (Topotecan and Cisplatin)	
Total subjects affected by serious adverse events			
subjects affected / exposed	37 / 83 (44.58%)	23 / 78 (29.49%)	
number of deaths (all causes)	65	61	
number of deaths resulting from adverse events	7	1	
Neoplasms benign, malignant and unspecified (incl cysts and polyps)			
Tumour pain			
subjects affected / exposed	0 / 83 (0.00%)	1 / 78 (1.28%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Vascular disorders			
Deep vein thrombosis			
subjects affected / exposed	0 / 83 (0.00%)	1 / 78 (1.28%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Venous thrombosis limb			
subjects affected / exposed	1 / 83 (1.20%)	0 / 78 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	

Surgical and medical procedures			
Nephrostomy tube removal			
subjects affected / exposed	1 / 83 (1.20%)	0 / 78 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
General disorders and administration site conditions			
Death			
subjects affected / exposed	2 / 83 (2.41%)	1 / 78 (1.28%)	
occurrences causally related to treatment / all	0 / 2	0 / 1	
deaths causally related to treatment / all	0 / 2	0 / 1	
Fatigue			
subjects affected / exposed	1 / 83 (1.20%)	0 / 78 (0.00%)	
occurrences causally related to treatment / all	1 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Pain			
subjects affected / exposed	0 / 83 (0.00%)	2 / 78 (2.56%)	
occurrences causally related to treatment / all	0 / 0	1 / 2	
deaths causally related to treatment / all	0 / 0	0 / 0	
Disease progression			
subjects affected / exposed	8 / 83 (9.64%)	2 / 78 (2.56%)	
occurrences causally related to treatment / all	1 / 8	0 / 2	
deaths causally related to treatment / all	1 / 1	0 / 0	
Reproductive system and breast disorders			
Vaginal haemorrhage			
subjects affected / exposed	1 / 83 (1.20%)	0 / 78 (0.00%)	
occurrences causally related to treatment / all	0 / 2	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Vaginal fistula			
subjects affected / exposed	2 / 83 (2.41%)	1 / 78 (1.28%)	
occurrences causally related to treatment / all	0 / 2	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Pleural effusion			

subjects affected / exposed	1 / 83 (1.20%)	1 / 78 (1.28%)	
occurrences causally related to treatment / all	0 / 2	1 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Respiratory, thoracic and mediastinal disorders			
Dyspnoea			
subjects affected / exposed	2 / 83 (2.41%)	1 / 78 (1.28%)	
occurrences causally related to treatment / all	0 / 3	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Pulmonary embolism			
subjects affected / exposed	3 / 83 (3.61%)	3 / 78 (3.85%)	
occurrences causally related to treatment / all	0 / 3	0 / 3	
deaths causally related to treatment / all	0 / 1	0 / 0	
Investigations			
Blood creatinine increased			
subjects affected / exposed	0 / 83 (0.00%)	2 / 78 (2.56%)	
occurrences causally related to treatment / all	0 / 0	1 / 3	
deaths causally related to treatment / all	0 / 0	0 / 0	
Body temperature increased			
subjects affected / exposed	2 / 83 (2.41%)	2 / 78 (2.56%)	
occurrences causally related to treatment / all	2 / 2	0 / 2	
deaths causally related to treatment / all	0 / 0	0 / 0	
General physical condition abnormal			
subjects affected / exposed	4 / 83 (4.82%)	0 / 78 (0.00%)	
occurrences causally related to treatment / all	3 / 6	0 / 0	
deaths causally related to treatment / all	0 / 2	0 / 0	
Injury, poisoning and procedural complications			
Spinal fracture			
subjects affected / exposed	0 / 83 (0.00%)	1 / 78 (1.28%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Cardiac disorders			
Sinus tachycardia			

subjects affected / exposed	1 / 83 (1.20%)	0 / 78 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Nervous system disorders			
Polyneuropathy in malignant disease			
subjects affected / exposed	1 / 83 (1.20%)	0 / 78 (0.00%)	
occurrences causally related to treatment / all	1 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Blood and lymphatic system disorders			
Anaemia			
subjects affected / exposed	9 / 83 (10.84%)	5 / 78 (6.41%)	
occurrences causally related to treatment / all	8 / 14	4 / 5	
deaths causally related to treatment / all	0 / 0	0 / 0	
Febrile neutropenia			
subjects affected / exposed	1 / 83 (1.20%)	3 / 78 (3.85%)	
occurrences causally related to treatment / all	1 / 1	3 / 3	
deaths causally related to treatment / all	0 / 0	0 / 0	
Leukopenia			
subjects affected / exposed	0 / 83 (0.00%)	2 / 78 (2.56%)	
occurrences causally related to treatment / all	0 / 0	2 / 2	
deaths causally related to treatment / all	0 / 0	0 / 0	
Neutropenia			
subjects affected / exposed	0 / 83 (0.00%)	3 / 78 (3.85%)	
occurrences causally related to treatment / all	0 / 0	3 / 3	
deaths causally related to treatment / all	0 / 0	0 / 0	
Thrombocytopenia			
subjects affected / exposed	0 / 83 (0.00%)	3 / 78 (3.85%)	
occurrences causally related to treatment / all	0 / 0	4 / 4	
deaths causally related to treatment / all	0 / 0	0 / 0	
Gastrointestinal disorders			
Abdominal pain			
subjects affected / exposed	1 / 83 (1.20%)	2 / 78 (2.56%)	
occurrences causally related to treatment / all	0 / 1	0 / 2	
deaths causally related to treatment / all	0 / 0	0 / 0	

Constipation			
subjects affected / exposed	1 / 83 (1.20%)	0 / 78 (0.00%)	
occurrences causally related to treatment / all	1 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Diarrhoea			
subjects affected / exposed	1 / 83 (1.20%)	0 / 78 (0.00%)	
occurrences causally related to treatment / all	1 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Gastritis			
subjects affected / exposed	0 / 83 (0.00%)	1 / 78 (1.28%)	
occurrences causally related to treatment / all	0 / 0	1 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Ileus			
subjects affected / exposed	1 / 83 (1.20%)	1 / 78 (1.28%)	
occurrences causally related to treatment / all	0 / 1	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Vomiting			
subjects affected / exposed	2 / 83 (2.41%)	0 / 78 (0.00%)	
occurrences causally related to treatment / all	0 / 2	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Subileus			
subjects affected / exposed	1 / 83 (1.20%)	3 / 78 (3.85%)	
occurrences causally related to treatment / all	0 / 1	1 / 3	
deaths causally related to treatment / all	0 / 0	0 / 0	
Enterocutaneous fistula			
subjects affected / exposed	1 / 83 (1.20%)	0 / 78 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Hepatobiliary disorders			
Liver disorder			
subjects affected / exposed	1 / 83 (1.20%)	0 / 78 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Bile duct obstruction			

subjects affected / exposed	1 / 83 (1.20%)	0 / 78 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Renal and urinary disorders			
Hydronephrosis			
subjects affected / exposed	1 / 83 (1.20%)	1 / 78 (1.28%)	
occurrences causally related to treatment / all	0 / 1	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Incontinence			
subjects affected / exposed	0 / 83 (0.00%)	1 / 78 (1.28%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Obstructive uropathy			
subjects affected / exposed	1 / 83 (1.20%)	0 / 78 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Renal failure			
subjects affected / exposed	1 / 83 (1.20%)	1 / 78 (1.28%)	
occurrences causally related to treatment / all	0 / 1	1 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Urinary tract obstruction			
subjects affected / exposed	0 / 83 (0.00%)	1 / 78 (1.28%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Musculoskeletal and connective tissue disorders			
Arthralgia			
subjects affected / exposed	1 / 83 (1.20%)	0 / 78 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Pain in extremity			
subjects affected / exposed	1 / 83 (1.20%)	0 / 78 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	

Spinal pain			
subjects affected / exposed	1 / 83 (1.20%)	0 / 78 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Infections and infestations			
Bacterial diarrhoea			
subjects affected / exposed	1 / 83 (1.20%)	0 / 78 (0.00%)	
occurrences causally related to treatment / all	0 / 2	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Cystitis			
subjects affected / exposed	0 / 83 (0.00%)	1 / 78 (1.28%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Erysipelas			
subjects affected / exposed	1 / 83 (1.20%)	0 / 78 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Infection			
subjects affected / exposed	0 / 83 (0.00%)	1 / 78 (1.28%)	
occurrences causally related to treatment / all	0 / 0	1 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Pneumonia			
subjects affected / exposed	1 / 83 (1.20%)	0 / 78 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Pyelonephritis			
subjects affected / exposed	1 / 83 (1.20%)	0 / 78 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Sepsis			
subjects affected / exposed	0 / 83 (0.00%)	1 / 78 (1.28%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Urethritis			

subjects affected / exposed	1 / 83 (1.20%)	0 / 78 (0.00%)	
occurrences causally related to treatment / all	0 / 4	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Urinary tract infection			
subjects affected / exposed	0 / 83 (0.00%)	3 / 78 (3.85%)	
occurrences causally related to treatment / all	0 / 0	1 / 3	
deaths causally related to treatment / all	0 / 0	0 / 0	
Urosepsis			
subjects affected / exposed	0 / 83 (0.00%)	1 / 78 (1.28%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Pulmonary sepsis			
subjects affected / exposed	1 / 83 (1.20%)	0 / 78 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 1	0 / 0	
Device related sepsis			
subjects affected / exposed	0 / 83 (0.00%)	1 / 78 (1.28%)	
occurrences causally related to treatment / all	0 / 0	1 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Campylobacter colitis			
subjects affected / exposed	1 / 83 (1.20%)	0 / 78 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Metabolism and nutrition disorders			
Dehydration			
subjects affected / exposed	1 / 83 (1.20%)	0 / 78 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	

Frequency threshold for reporting non-serious adverse events: 1 %

Non-serious adverse events	Arm A (Paclitaxel and Topotecan)	Arm B (Topotecan and Cisplatin)	
Total subjects affected by non-serious adverse events			
subjects affected / exposed	83 / 83 (100.00%)	77 / 78 (98.72%)	
Neoplasms benign, malignant and unspecified (incl cysts and polyps)			
Tumour pain			
subjects affected / exposed	1 / 83 (1.20%)	6 / 78 (7.69%)	
occurrences (all)	1	9	
Tumour associated fever			
subjects affected / exposed	0 / 83 (0.00%)	1 / 78 (1.28%)	
occurrences (all)	0	1	
Cancer pain			
subjects affected / exposed	1 / 83 (1.20%)	1 / 78 (1.28%)	
occurrences (all)	1	1	
Vascular disorders			
Flushing			
subjects affected / exposed	2 / 83 (2.41%)	0 / 78 (0.00%)	
occurrences (all)	2	0	
Hypertension			
subjects affected / exposed	0 / 83 (0.00%)	1 / 78 (1.28%)	
occurrences (all)	0	4	
Lymphoedema			
subjects affected / exposed	0 / 83 (0.00%)	1 / 78 (1.28%)	
occurrences (all)	0	2	
Pelvic venous thrombosis			
subjects affected / exposed	1 / 83 (1.20%)	0 / 78 (0.00%)	
occurrences (all)	1	0	
Thrombosis			
subjects affected / exposed	2 / 83 (2.41%)	0 / 78 (0.00%)	
occurrences (all)	2	0	
Deep vein thrombosis			
subjects affected / exposed	1 / 83 (1.20%)	2 / 78 (2.56%)	
occurrences (all)	1	7	
Hot flush			
subjects affected / exposed	2 / 83 (2.41%)	4 / 78 (5.13%)	
occurrences (all)	2	15	
Venous thrombosis limb			

subjects affected / exposed	2 / 83 (2.41%)	0 / 78 (0.00%)
occurrences (all)	3	0
General disorders and administration site conditions		
Asthenia		
subjects affected / exposed	1 / 83 (1.20%)	0 / 78 (0.00%)
occurrences (all)	1	0
Chest discomfort		
subjects affected / exposed	1 / 83 (1.20%)	0 / 78 (0.00%)
occurrences (all)	1	0
Chest pain		
subjects affected / exposed	0 / 83 (0.00%)	1 / 78 (1.28%)
occurrences (all)	0	1
Chills		
subjects affected / exposed	1 / 83 (1.20%)	2 / 78 (2.56%)
occurrences (all)	1	3
Fatigue		
subjects affected / exposed	59 / 83 (71.08%)	59 / 78 (75.64%)
occurrences (all)	155	181
Hernia		
subjects affected / exposed	1 / 83 (1.20%)	0 / 78 (0.00%)
occurrences (all)	1	0
Mucosal dryness		
subjects affected / exposed	0 / 83 (0.00%)	1 / 78 (1.28%)
occurrences (all)	0	1
Oedema		
subjects affected / exposed	34 / 83 (40.96%)	22 / 78 (28.21%)
occurrences (all)	86	50
Pain		
subjects affected / exposed	5 / 83 (6.02%)	8 / 78 (10.26%)
occurrences (all)	6	23
Peripheral swelling		
subjects affected / exposed	1 / 83 (1.20%)	0 / 78 (0.00%)
occurrences (all)	1	0
Infusion site extravasation		

subjects affected / exposed occurrences (all)	1 / 83 (1.20%) 1	0 / 78 (0.00%) 0	
Immune system disorders Hypersensitivity subjects affected / exposed occurrences (all)	9 / 83 (10.84%) 11	4 / 78 (5.13%) 6	
Social circumstances Rash subjects affected / exposed occurrences (all)	2 / 83 (2.41%) 2	0 / 78 (0.00%) 0	
Reproductive system and breast disorders Breast disorder female subjects affected / exposed occurrences (all)	0 / 83 (0.00%) 0	1 / 78 (1.28%) 1	
Breast pain subjects affected / exposed occurrences (all)	1 / 83 (1.20%) 1	0 / 78 (0.00%) 0	
Pelvic pain subjects affected / exposed occurrences (all)	2 / 83 (2.41%) 3	1 / 78 (1.28%) 1	
Vaginal discharge subjects affected / exposed occurrences (all)	1 / 83 (1.20%) 1	2 / 78 (2.56%) 3	
Vaginal haemorrhage subjects affected / exposed occurrences (all)	1 / 83 (1.20%) 1	2 / 78 (2.56%) 2	
Female genital tract fistula subjects affected / exposed occurrences (all)	0 / 83 (0.00%) 0	1 / 78 (1.28%) 1	
Perineal pain subjects affected / exposed occurrences (all)	1 / 83 (1.20%) 1	0 / 78 (0.00%) 0	
Genital lesion subjects affected / exposed occurrences (all)	1 / 83 (1.20%) 3	0 / 78 (0.00%) 0	
Vaginal fistula			

subjects affected / exposed occurrences (all)	0 / 83 (0.00%) 0	1 / 78 (1.28%) 3	
Vulvovaginal burning sensation subjects affected / exposed occurrences (all)	0 / 83 (0.00%) 0	1 / 78 (1.28%) 1	
Vulvovaginal pain subjects affected / exposed occurrences (all)	1 / 83 (1.20%) 2	0 / 78 (0.00%) 0	
Respiratory, thoracic and mediastinal disorders			
Cough subjects affected / exposed occurrences (all)	3 / 83 (3.61%) 4	2 / 78 (2.56%) 3	
Dyspnoea subjects affected / exposed occurrences (all)	24 / 83 (28.92%) 46	16 / 78 (20.51%) 42	
Epistaxis subjects affected / exposed occurrences (all)	2 / 83 (2.41%) 2	1 / 78 (1.28%) 2	
Pleural effusion subjects affected / exposed occurrences (all)	1 / 83 (1.20%) 1	1 / 78 (1.28%) 1	
Larynx irritation subjects affected / exposed occurrences (all)	2 / 83 (2.41%) 2	0 / 78 (0.00%) 0	
Oropharyngeal pain subjects affected / exposed occurrences (all)	2 / 83 (2.41%) 2	1 / 78 (1.28%) 1	
Psychiatric disorders			
Anxiety subjects affected / exposed occurrences (all)	0 / 83 (0.00%) 0	1 / 78 (1.28%) 1	
Depression subjects affected / exposed occurrences (all)	0 / 83 (0.00%) 0	1 / 78 (1.28%) 1	
Insomnia			

subjects affected / exposed occurrences (all)	0 / 83 (0.00%) 0	1 / 78 (1.28%) 1	
Sleep disorder subjects affected / exposed occurrences (all)	2 / 83 (2.41%) 2	1 / 78 (1.28%) 1	
Investigations			
Alanine aminotransferase increased subjects affected / exposed occurrences (all)	25 / 83 (30.12%) 61	21 / 78 (26.92%) 37	
Aspartate aminotransferase increased subjects affected / exposed occurrences (all)	22 / 83 (26.51%) 36	22 / 78 (28.21%) 38	
Blood bilirubin increased subjects affected / exposed occurrences (all)	7 / 83 (8.43%) 9	6 / 78 (7.69%) 9	
Blood calcium decreased subjects affected / exposed occurrences (all)	21 / 83 (25.30%) 37	31 / 78 (39.74%) 48	
Blood calcium increased subjects affected / exposed occurrences (all)	7 / 83 (8.43%) 10	2 / 78 (2.56%) 48	
Blood creatinine increased subjects affected / exposed occurrences (all)	25 / 83 (30.12%) 50	24 / 78 (30.77%) 75	
Blood lactate dehydrogenase increased subjects affected / exposed occurrences (all)	37 / 83 (44.58%) 84	36 / 78 (46.15%) 83	
Blood magnesium decreased subjects affected / exposed occurrences (all)	23 / 83 (27.71%) 33	35 / 78 (44.87%) 77	
Blood magnesium increased subjects affected / exposed occurrences (all)	3 / 83 (3.61%) 3	4 / 78 (5.13%) 4	
Blood potassium decreased			

subjects affected / exposed	20 / 83 (24.10%)	18 / 78 (23.08%)
occurrences (all)	28	27
Blood potassium increased		
subjects affected / exposed	17 / 83 (20.48%)	15 / 78 (19.23%)
occurrences (all)	20	26
Blood sodium decreased		
subjects affected / exposed	19 / 83 (22.89%)	23 / 78 (29.49%)
occurrences (all)	22	45
Blood sodium increased		
subjects affected / exposed	4 / 83 (4.82%)	5 / 78 (6.41%)
occurrences (all)	4	7
Body temperature increased		
subjects affected / exposed	4 / 83 (4.82%)	6 / 78 (7.69%)
occurrences (all)	4	9
Creatinine renal clearance increased		
subjects affected / exposed	0 / 83 (0.00%)	1 / 78 (1.28%)
occurrences (all)	0	1
Gamma-glutamyltransferase increased		
subjects affected / exposed	51 / 83 (61.45%)	52 / 78 (66.67%)
occurrences (all)	133	169
Weight decreased		
subjects affected / exposed	0 / 83 (0.00%)	1 / 78 (1.28%)
occurrences (all)	0	1
Blood phosphorus increased		
subjects affected / exposed	0 / 83 (0.00%)	1 / 78 (1.28%)
occurrences (all)	0	1
Transaminases increased		
subjects affected / exposed	1 / 83 (1.20%)	0 / 78 (0.00%)
occurrences (all)	1	0
General physical condition abnormal		
subjects affected / exposed	1 / 83 (1.20%)	0 / 78 (0.00%)
occurrences (all)	1	0
Blood alkaline phosphatase increased		
subjects affected / exposed	36 / 83 (43.37%)	36 / 78 (46.15%)
occurrences (all)	87	92

Urine analysis abnormal subjects affected / exposed occurrences (all)	38 / 83 (45.78%) 75	39 / 78 (50.00%) 74	
Injury, poisoning and procedural complications			
Radius fracture subjects affected / exposed occurrences (all)	0 / 83 (0.00%) 0	1 / 78 (1.28%) 1	
Lumbar vertebral fracture subjects affected / exposed occurrences (all)	0 / 83 (0.00%) 0	1 / 78 (1.28%) 1	
Thoracic vertebral fracture subjects affected / exposed occurrences (all)	0 / 83 (0.00%) 0	1 / 78 (1.28%) 1	
Cardiac disorders			
Cardiovascular disorder subjects affected / exposed occurrences (all)	6 / 83 (7.23%) 9	3 / 78 (3.85%) 4	
Sinus tachycardia subjects affected / exposed occurrences (all)	1 / 83 (1.20%) 1	0 / 78 (0.00%) 0	
Nervous system disorders			
Ageusia subjects affected / exposed occurrences (all)	2 / 83 (2.41%) 2	1 / 78 (1.28%) 2	
Dizziness subjects affected / exposed occurrences (all)	3 / 83 (3.61%) 4	3 / 78 (3.85%) 6	
Dysaesthesia subjects affected / exposed occurrences (all)	1 / 83 (1.20%) 1	1 / 78 (1.28%) 1	
Dysarthria subjects affected / exposed occurrences (all)	0 / 83 (0.00%) 0	1 / 78 (1.28%) 1	
Headache subjects affected / exposed occurrences (all)	3 / 83 (3.61%) 4	5 / 78 (6.41%) 7	

Monoparesis			
subjects affected / exposed	0 / 83 (0.00%)	1 / 78 (1.28%)	
occurrences (all)	0	1	
Neurotoxicity			
subjects affected / exposed	35 / 83 (42.17%)	21 / 78 (26.92%)	
occurrences (all)	100	49	
Polyneuropathy in malignant disease			
subjects affected / exposed	0 / 83 (0.00%)	1 / 78 (1.28%)	
occurrences (all)	0	2	
Sciatica			
subjects affected / exposed	1 / 83 (1.20%)	0 / 78 (0.00%)	
occurrences (all)	1	0	
Radicular syndrome			
subjects affected / exposed	0 / 83 (0.00%)	1 / 78 (1.28%)	
occurrences (all)	0	1	
Blood and lymphatic system disorders			
Anaemia			
subjects affected / exposed	82 / 83 (98.80%)	76 / 78 (97.44%)	
occurrences (all)	1075	832	
Febrile neutropenia			
subjects affected / exposed	3 / 83 (3.61%)	4 / 78 (5.13%)	
occurrences (all)	3	4	
Leukopenia			
subjects affected / exposed	64 / 83 (77.11%)	74 / 78 (94.87%)	
occurrences (all)	381	468	
Neutropenia			
subjects affected / exposed	45 / 83 (54.22%)	61 / 78 (78.21%)	
occurrences (all)	117	264	
Pancytopenia			
subjects affected / exposed	0 / 83 (0.00%)	1 / 78 (1.28%)	
occurrences (all)	0	1	
Thrombocytopenia			
subjects affected / exposed	23 / 83 (27.71%)	55 / 78 (70.51%)	
occurrences (all)	60	243	
Ear and labyrinth disorders			

Deafness			
subjects affected / exposed	0 / 83 (0.00%)	1 / 78 (1.28%)	
occurrences (all)	0	1	
Ototoxicity			
subjects affected / exposed	1 / 83 (1.20%)	0 / 78 (0.00%)	
occurrences (all)	1	0	
Vertigo			
subjects affected / exposed	0 / 83 (0.00%)	2 / 78 (2.56%)	
occurrences (all)	0	2	
Eye disorders			
Eye pain			
subjects affected / exposed	1 / 83 (1.20%)	0 / 78 (0.00%)	
occurrences (all)	2	0	
Vision blurred			
subjects affected / exposed	0 / 83 (0.00%)	1 / 78 (1.28%)	
occurrences (all)	0	1	
Gastrointestinal disorders			
Abdominal discomfort			
subjects affected / exposed	1 / 83 (1.20%)	0 / 78 (0.00%)	
occurrences (all)	1	0	
Abdominal pain			
subjects affected / exposed	1 / 83 (1.20%)	8 / 78 (10.26%)	
occurrences (all)	6	9	
Abdominal pain lower			
subjects affected / exposed	7 / 83 (8.43%)	6 / 78 (7.69%)	
occurrences (all)	8	11	
Abdominal pain upper			
subjects affected / exposed	2 / 83 (2.41%)	5 / 78 (6.41%)	
occurrences (all)	2	5	
Ascites			
subjects affected / exposed	0 / 83 (0.00%)	1 / 78 (1.28%)	
occurrences (all)	0	1	
Colitis			
subjects affected / exposed	1 / 83 (1.20%)	0 / 78 (0.00%)	
occurrences (all)	1	0	
Constipation			

subjects affected / exposed	27 / 83 (32.53%)	33 / 78 (42.31%)
occurrences (all)	43	68
Diarrhoea		
subjects affected / exposed	30 / 83 (36.14%)	26 / 78 (33.33%)
occurrences (all)	51	49
Dry mouth		
subjects affected / exposed	1 / 83 (1.20%)	0 / 78 (0.00%)
occurrences (all)	1	0
Dysphagia		
subjects affected / exposed	0 / 83 (0.00%)	1 / 78 (1.28%)
occurrences (all)	0	1
Flatulence		
subjects affected / exposed	1 / 83 (1.20%)	2 / 78 (2.56%)
occurrences (all)	1	2
Gastric haemorrhage		
subjects affected / exposed	0 / 83 (0.00%)	1 / 78 (1.28%)
occurrences (all)	0	1
Gastrooesophageal reflux disease		
subjects affected / exposed	2 / 83 (2.41%)	3 / 78 (3.85%)
occurrences (all)	3	4
Gastrointestinal pain		
subjects affected / exposed	1 / 83 (1.20%)	0 / 78 (0.00%)
occurrences (all)	1	0
Haematochezia		
subjects affected / exposed	1 / 83 (1.20%)	1 / 78 (1.28%)
occurrences (all)	1	1
Ileus		
subjects affected / exposed	2 / 83 (2.41%)	0 / 78 (0.00%)
occurrences (all)	2	0
Nausea		
subjects affected / exposed	35 / 83 (42.17%)	52 / 78 (66.67%)
occurrences (all)	78	134
Rectal haemorrhage		
subjects affected / exposed	1 / 83 (1.20%)	1 / 78 (1.28%)
occurrences (all)	1	1
Stomatitis		

subjects affected / exposed occurrences (all)	15 / 83 (18.07%) 26	13 / 78 (16.67%) 23	
Vomiting subjects affected / exposed occurrences (all)	22 / 83 (26.51%) 36	29 / 78 (37.18%) 56	
Subileus subjects affected / exposed occurrences (all)	0 / 83 (0.00%) 0	1 / 78 (1.28%) 1	
Dyschezia subjects affected / exposed occurrences (all)	1 / 83 (1.20%) 1	0 / 78 (0.00%) 0	
Enterocutaneous fistula subjects affected / exposed occurrences (all)	1 / 83 (1.20%) 1	0 / 78 (0.00%) 0	
Tooth pulp haemorrhage subjects affected / exposed occurrences (all)	0 / 83 (0.00%) 0	1 / 78 (1.28%) 1	
Hepatobiliary disorders Liver disorder subjects affected / exposed occurrences (all)	1 / 83 (1.20%) 2	0 / 78 (0.00%) 0	
Bile duct obstruction subjects affected / exposed occurrences (all)	1 / 83 (1.20%) 1	0 / 78 (0.00%) 0	
Skin and subcutaneous tissue disorders Alopecia subjects affected / exposed occurrences (all)	58 / 83 (69.88%) 69	53 / 78 (67.95%) 196	
Dry skin subjects affected / exposed occurrences (all)	0 / 83 (0.00%) 0	2 / 78 (2.56%) 2	
Neurodermatitis subjects affected / exposed occurrences (all)	0 / 83 (0.00%) 0	1 / 78 (1.28%) 1	
Night sweats			

subjects affected / exposed	1 / 83 (1.20%)	1 / 78 (1.28%)	
occurrences (all)	1	1	
Palmar-plantar erythrodysesthesia syndrome			
subjects affected / exposed	0 / 83 (0.00%)	1 / 78 (1.28%)	
occurrences (all)	0	1	
Petechiae			
subjects affected / exposed	0 / 83 (0.00%)	1 / 78 (1.28%)	
occurrences (all)	0	4	
Skin hyperpigmentation			
subjects affected / exposed	1 / 83 (1.20%)	0 / 78 (0.00%)	
occurrences (all)	1	0	
Swelling face			
subjects affected / exposed	1 / 83 (1.20%)	0 / 78 (0.00%)	
occurrences (all)	1	0	
Nail pigmentation			
subjects affected / exposed	2 / 83 (2.41%)	1 / 78 (1.28%)	
occurrences (all)	4	2	
Renal and urinary disorders			
Bladder discomfort			
subjects affected / exposed	1 / 83 (1.20%)	0 / 78 (0.00%)	
occurrences (all)	1	0	
Bladder pain			
subjects affected / exposed	1 / 83 (1.20%)	0 / 78 (0.00%)	
occurrences (all)	1	0	
Dysuria			
subjects affected / exposed	0 / 83 (0.00%)	2 / 78 (2.56%)	
occurrences (all)	0	2	
Haematuria			
subjects affected / exposed	4 / 83 (4.82%)	1 / 78 (1.28%)	
occurrences (all)	6	1	
Hydronephrosis			
subjects affected / exposed	2 / 83 (2.41%)	1 / 78 (1.28%)	
occurrences (all)	2	1	
Incontinence			

subjects affected / exposed	3 / 83 (3.61%)	0 / 78 (0.00%)
occurrences (all)	7	0
Nocturia		
subjects affected / exposed	2 / 83 (2.41%)	0 / 78 (0.00%)
occurrences (all)	2	0
Pollakiuria		
subjects affected / exposed	1 / 83 (1.20%)	0 / 78 (0.00%)
occurrences (all)	1	0
Renal disorder		
subjects affected / exposed	1 / 83 (1.20%)	0 / 78 (0.00%)
occurrences (all)	1	0
Renal failure		
subjects affected / exposed	0 / 83 (0.00%)	1 / 78 (1.28%)
occurrences (all)	0	1
Renal pain		
subjects affected / exposed	1 / 83 (1.20%)	1 / 78 (1.28%)
occurrences (all)	1	1
Urine abnormality		
subjects affected / exposed	1 / 83 (1.20%)	0 / 78 (0.00%)
occurrences (all)	1	0
Urogenital fistula		
subjects affected / exposed	1 / 83 (1.20%)	1 / 78 (1.28%)
occurrences (all)	1	1
Urinary tract obstruction		
subjects affected / exposed	1 / 83 (1.20%)	2 / 78 (2.56%)
occurrences (all)	1	2
Urinary tract pain		
subjects affected / exposed	1 / 83 (1.20%)	0 / 78 (0.00%)
occurrences (all)	1	0
Stress urinary incontinence		
subjects affected / exposed	0 / 83 (0.00%)	1 / 78 (1.28%)
occurrences (all)	0	1
Urinary tract discomfort		
subjects affected / exposed	2 / 83 (2.41%)	0 / 78 (0.00%)
occurrences (all)	2	0
Musculoskeletal and connective tissue		

disorders			
Arthralgia			
subjects affected / exposed	15 / 83 (18.07%)	16 / 78 (20.51%)	
occurrences (all)	18	23	
Back pain			
subjects affected / exposed	3 / 83 (3.61%)	2 / 78 (2.56%)	
occurrences (all)	6	4	
Bone pain			
subjects affected / exposed	2 / 83 (2.41%)	2 / 78 (2.56%)	
occurrences (all)	8	2	
Myalgia			
subjects affected / exposed	15 / 83 (18.07%)	12 / 78 (15.38%)	
occurrences (all)	24	22	
Neck pain			
subjects affected / exposed	1 / 83 (1.20%)	0 / 78 (0.00%)	
occurrences (all)	5	0	
Pain in extremity			
subjects affected / exposed	4 / 83 (4.82%)	3 / 78 (3.85%)	
occurrences (all)	5	5	
Musculoskeletal stiffness			
subjects affected / exposed	0 / 83 (0.00%)	1 / 78 (1.28%)	
occurrences (all)	0	1	
Spinal pain			
subjects affected / exposed	5 / 83 (6.02%)	4 / 78 (5.13%)	
occurrences (all)	7	8	
Infections and infestations			
Bronchitis			
subjects affected / exposed	0 / 83 (0.00%)	1 / 78 (1.28%)	
occurrences (all)	0	1	
Conjunctivitis			
subjects affected / exposed	0 / 83 (0.00%)	1 / 78 (1.28%)	
occurrences (all)	0	1	
Cystitis			
subjects affected / exposed	7 / 83 (8.43%)	5 / 78 (6.41%)	
occurrences (all)	8	5	
Erysipelas			

subjects affected / exposed	1 / 83 (1.20%)	0 / 78 (0.00%)
occurrences (all)	1	0
Fungal skin infection		
subjects affected / exposed	1 / 83 (1.20%)	0 / 78 (0.00%)
occurrences (all)	3	0
Gastroenteritis		
subjects affected / exposed	1 / 83 (1.20%)	0 / 78 (0.00%)
occurrences (all)	1	0
Herpes simplex		
subjects affected / exposed	1 / 83 (1.20%)	0 / 78 (0.00%)
occurrences (all)	1	0
Infection		
subjects affected / exposed	17 / 83 (20.48%)	15 / 78 (19.23%)
occurrences (all)	21	17
Influenza		
subjects affected / exposed	1 / 83 (1.20%)	0 / 78 (0.00%)
occurrences (all)	1	0
Pyelonephritis		
subjects affected / exposed	1 / 83 (1.20%)	0 / 78 (0.00%)
occurrences (all)	1	0
Rash pustular		
subjects affected / exposed	1 / 83 (1.20%)	0 / 78 (0.00%)
occurrences (all)	1	0
Sinusitis		
subjects affected / exposed	0 / 83 (0.00%)	1 / 78 (1.28%)
occurrences (all)	0	1
Upper respiratory tract infection		
subjects affected / exposed	3 / 83 (3.61%)	2 / 78 (2.56%)
occurrences (all)	4	3
Urethritis		
subjects affected / exposed	1 / 83 (1.20%)	0 / 78 (0.00%)
occurrences (all)	1	0
Urinary tract infection		
subjects affected / exposed	2 / 83 (2.41%)	2 / 78 (2.56%)
occurrences (all)	2	4
Vulvitis		

subjects affected / exposed occurrences (all)	1 / 83 (1.20%) 1	0 / 78 (0.00%) 0	
Urosepsis subjects affected / exposed occurrences (all)	0 / 83 (0.00%) 0	1 / 78 (1.28%) 1	
Vascular access site infection subjects affected / exposed occurrences (all)	1 / 83 (1.20%) 1	0 / 78 (0.00%) 0	
Metabolism and nutrition disorders			
Cachexia subjects affected / exposed occurrences (all)	1 / 83 (1.20%) 1	0 / 78 (0.00%) 0	
Hyperglycaemia subjects affected / exposed occurrences (all)	0 / 83 (0.00%) 0	1 / 78 (1.28%) 1	
Weight fluctuation subjects affected / exposed occurrences (all)	1 / 83 (1.20%) 1	0 / 78 (0.00%) 0	
Malnutrition subjects affected / exposed occurrences (all)	1 / 83 (1.20%) 1	0 / 78 (0.00%) 0	
Decreased appetite subjects affected / exposed occurrences (all)	1 / 83 (1.20%) 2	2 / 78 (2.56%) 4	

More information

Substantial protocol amendments (globally)

Were there any global substantial amendments to the protocol? Yes

Date	Amendment
05 September 2011	<p>After a 2-year extension of the recruitment period and slow recruitment (172 of 312 planned patients) an amendment of the study protocol (Amendment 1; protocol Version 2) was accepted by the IEC to perform an interim analysis, to check if a continuation of the study could answer the primary objective (difference in overall survival). An adaptive interim analysis (AIA) was performed on February 27th 2012. The AIA allows sample size re-calculation for the second stage of the trial after the interim analysis or, if the case may be, early stopping of the trial after the interim analysis. In the first case, a final p-value is calculated from the p-values of both stages. In the second case, the p-value of the interim analysis is the p-value of the primary objective. The following parameters were selected for the planning of the two phases of the study (first phase up to AIA, second phase after AIA: a global $\alpha = 0.05$ (two-sided) and the total power of 80%. Let p_1 be the p-value for the statistical test of the interim analysis. $\alpha_0 = 0.5$ was the critical lower limit, so that for $p_1 \geq \alpha_0$, the interim analysis would lead to early stopping with the acceptance of the null hypothesis ("no treatment effect"). One would also stop if a treatment difference has been estimated that does not indicate the intended direction. $\alpha_1 = 0.0233$ was critical upper limit, so that for $p_1 < \alpha_1$ the interim analysis would stop with the rejection of the null hypothesis. If p_1 was between α_1 and α_0 and the estimated treatment difference indicates the intended direction, a second study phase would be planned. The interim analysis revealed no significant difference in overall survival rates, but a trend toward superiority of the control group (Arm B). From a statistical perspective, continuing recruitment to demonstrate superiority of arm A was not reasonable; therefore, recruitment was terminated after the interim analysis. Patients were allowed to continue trial therapy that had already been started.</p>

Notes:

Interruptions (globally)

Were there any global interruptions to the trial? Yes

Date	Interruption	Restart date
31 December 2012	<p>Recruitment was stopped on 31-Dec-2011 for preparation of an interim analysis. The interim analysis performed on 27-Apr-2012 revealed no significant difference in overall survival rates, but a trend toward superiority of the control group (Arm B). From a statistical perspective, continuing recruitment to demonstrate superiority of arm A was not reasonable; therefore, recruitment was terminated after the interim analysis. At the same time, since there were no safety concerns identified from the safety report, patients were allowed to continue effective therapy that had already been started.</p>	-

Notes:

Limitations and caveats

None reported